Oncology Institute (TOI) Q4 2025: Pharmacy Revenue Jumps 71%, Accelerating Capitated Platform Leverage
TOI’s Q4 marked a turning point, posting its first positive adjusted EBITDA as pharmacy and delegated capitation models scaled rapidly. The company’s hybrid care model and payer partnership expansion drove record revenue and margin gains, with pharmacy and capitated contracts now powering both top-line momentum and operational leverage. 2026 guidance underscores a disciplined, growth-focused roadmap, but investors should monitor margin dynamics as delegated contracts ramp and sector reimbursement pressures intensify.
Summary
- Delegated Capitation Model Drives Revenue Mix Shift: Rapid expansion of high-value contracts is reshaping growth and margin profile.
- Pharmacy Platform Surges: Dispensing revenue and gross profit outperformance now central to TOI’s operating leverage and cash flow story.
- 2026 Focus on Profitability and Scale: Execution on hybrid model and disciplined cost structure will determine long-term margin sustainability.
Performance Analysis
TOI delivered a breakout quarter, achieving positive adjusted EBITDA for the first time as a public company, underpinned by a 41.6% year-over-year revenue surge in Q4. The engine of this growth was pharmacy, which accounted for 57.4% of Q4 revenue and soared 71.1% year-over-year as prescription attachment and in-clinic dispensing improved sharply. Patient services, comprising both fee-for-service (FFS, traditional per-visit reimbursement) and capitation (fixed per-member per-month contracts), also grew but at a more measured pace, together representing 42.2% of total revenue.
Gross margin expanded by 140 basis points year-over-year, reflecting not only pharmacy optimization but also disciplined clinical utilization and improved drug procurement. Operating leverage was visible in SG&A, which declined over 500 basis points as a share of revenue, even as the company invested for future growth. The hybrid care model—leveraging both TOI-owned and network clinics—enabled rapid scaling of delegated contracts and provided a platform for multi-market expansion without commensurate overhead increases.
- Pharmacy Revenue Outperformance: Pharmacy segment revenue reached $81.4 million in Q4, representing the majority of growth and driving an 84.7% increase in pharmacy gross profit.
- Delegated Capitation Acceleration: Florida delegated contracts now represent about a third of capitated revenue run rate, despite being less than 5% of total capitated lives.
- SG&A Leverage Materializes: Operating expenses fell to 19.7% of revenue, unlocking positive adjusted EBITDA and supporting free cash flow improvement.
TOI’s balance sheet strengthened with positive free cash flow in Q4 and a $24 million reduction in convertible preferred note debt, leaving $33.6 million in cash to fund continued platform expansion.
Executive Commentary
"The biggest driver of this progress continues to be the expansion of our capitated care model, particularly through our delegated arrangements, which enables us to manage the oncology benefit more comprehensively while aligning incentives with our payer partners across markets and delivering quality clinical outcomes to the patients that we serve."
Dan Vernick, Chief Executive Officer
"Pharmacy revenue was $81.4 million, representing 57.4% of total revenue, and increased 71.1% year over year, driven by higher prescription volumes and expanded pharmacy attachment within our clinics, which was a key operational focus for us over the course of the year."
Rob Carter, Chief Financial Officer
Strategic Positioning
1. Delegated Capitation Model as Growth Catalyst
TOI’s delegated capitation model—where the company assumes full responsibility for oncology care costs for defined member populations—has become a central strategic lever. These contracts, especially in Florida, deliver higher per-member economics and allow TOI to directly manage clinical utilization (Medical Loss Ratio, or MLR, is a key metric here, indicating the share of premium spent on medical care). With delegated lives now accounting for a third of run rate capitated revenue, despite being a small fraction of total lives, the model is shifting the company’s revenue mix toward higher-margin, recurring revenue streams.
2. Pharmacy Platform Integration and Expansion
TOI’s in-house Part D dispensing platform has emerged as a core profit and cash flow driver. By capturing more scripts within TOI’s network and reducing leakage to outside specialty pharmacies, pharmacy revenue nearly doubled year-over-year. This platform supports margin expansion through improved procurement and utilization management, and enables cross-sell opportunities with both employed and network-affiliated providers.
3. Hybrid Network Model Enables Scalable Growth
The hybrid model—blending TOI-owned clinics with a growing network of independent providers—enables rapid payer partnership expansion without linear cost increases. In Florida, the affiliated provider network grew to over 200, supporting both delegated and traditional capitation. This structure allows for flexible deployment, capital efficiency, and faster time-to-market when launching new contracts.
4. Technology and AI-Driven Efficiency
TOI is investing in a proprietary network portal and AI-driven automation for prior authorization, revenue cycle management (RCM), and call center operations, targeting $2 million in SG&A savings in 2026. These initiatives are designed to drive both cost reduction and quality improvements, with early results showing faster prior auth turnaround and improved patient care metrics.
5. Leadership and Board Strengthening
Recent additions to the executive team and board bring deep healthcare, pharmacy, and financial expertise, providing additional capability as TOI scales its platform and pursues multi-state growth. The company’s ability to attract experienced leadership signals confidence in the long-term trajectory and supports disciplined execution on its growth roadmap.
Key Considerations
TOI’s Q4 and full-year results reveal a business at an inflection point, with recurring, high-margin revenue streams scaling and operational leverage emerging. The company’s ability to execute on delegated capitation, pharmacy integration, and cost discipline will define its trajectory as it moves toward sustainable profitability.
Key Considerations:
- Delegated Capitation Ramp: Expansion in Florida and new payer wins (Humana, Care Plus) position TOI for multi-year growth, but will require careful MLR management as patient risk pools evolve.
- Pharmacy Attachment and Margin: Continued gains in prescription capture and supply chain optimization are vital for gross profit expansion and cash generation.
- SG&A Control Amid Growth: While operating leverage is improving, future investments in technology and network expansion must be balanced against margin preservation goals.
- Reimbursement and Regulatory Dynamics: IRA (Inflation Reduction Act) drug pricing impacts are expected to be minimal in 2026, but broader Medicare Advantage rate pressures could reshape payer negotiations and contract economics.
Risks
Rapid delegated contract growth introduces MLR volatility, especially as new patient cohorts ramp and utilization trends emerge. Sector-wide Medicare Advantage reimbursement pressures may intensify payer negotiations, potentially challenging contract pricing and renewal terms. Pharmacy revenue concentration creates exposure to drug pricing and supply chain dynamics, while ongoing investments in technology and network expansion must be matched by execution discipline to avoid margin dilution.
Forward Outlook
For Q1 2026, TOI guided to:
- Adjusted EBITDA loss between $3 million and $1 million, reflecting seasonal deductible resets and lagged reimbursement for drug price increases.
For full-year 2026, management reiterated guidance:
- Revenue of $630 million to $650 million
- Capitated revenue of approximately $150 million
- Gross profit of $97 million to $107 million
- Adjusted EBITDA of $0 to $9 million
- Free cash flow of negative $15 million to $5 million, with positive inflection expected by year-end
Management emphasized:
- Continued strong delegated capitation growth, especially in Florida, with the goal of doubling the Elevance partnership
- Pharmacy performance in line with recent run rates, plus incremental growth from new capitation lives
- SG&A as a percentage of revenue to trend toward 16% as scale is realized
Takeaways
TOI’s Q4 results confirm a business model pivoting toward recurring, high-margin revenue streams with operational leverage beginning to materialize.
- Delegated Capitation and Pharmacy Synergy: The combination of delegated contracts and pharmacy integration is reshaping TOI’s revenue and profit profile, making execution on both fronts critical for 2026 and beyond.
- Disciplined Expansion and Margin Focus: While growth opportunities abound, especially in Florida, maintaining MLR discipline and SG&A control will be key to sustaining profitability and cash flow.
- Watch for Margin Inflection and Payer Dynamics: Investors should monitor the impact of new contract ramp, sector reimbursement changes, and pharmacy attachment rates as leading indicators for future quarters.
Conclusion
TOI exits 2025 with clear momentum, leveraging its hybrid care and pharmacy platform to drive both top-line growth and margin expansion. The path to sustainable profitability now hinges on disciplined execution in delegated capitation, pharmacy integration, and SG&A control, as the company navigates sector headwinds and competitive payer dynamics.
Industry Read-Through
TOI’s results highlight the growing importance of delegated capitation and pharmacy integration in value-based oncology care. The ability to align incentives with payers, optimize medical loss ratios, and drive recurring revenue through in-house dispensing is becoming a key differentiator in the sector. Other specialty care platforms and physician groups should note the operational leverage unlocked by hybrid network models and technology-driven utilization management. Sector-wide, Medicare Advantage reimbursement pressure is likely to accelerate payer-provider partnerships focused on cost containment and quality outcomes, favoring platforms with demonstrated MLR control and scalable care models.